March 2023 in “The Journal of Urology” Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.
66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
March 2023 in “Reactions Weekly”
April 2024 in “JEADV clinical practice” Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
5 citations
,
January 2024 in “Journal of Cancer” The treatment combination is effective and generally safe for lung cancer.
7 citations
,
April 2021 in “British Journal of Dermatology” Topical tofacitinib may effectively and safely regrow facial hair in some people with alopecia areata.
6 citations
,
February 2023 in “Advances in Therapy” Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
39 citations
,
August 2022 in “Pharmaceutics” Combining letrozole and quercetin in spanlastics may improve breast cancer treatment.
ISX9 helps regrow hair by activating a specific cell signaling pathway.
25 citations
,
March 2017 in “International Journal of Dermatology” Ruxolitinib effectively and safely regrows hair in alopecia patients.
6 citations
,
November 2022 in “Antioxidants” OR2AT4 helps reduce aging and cell damage in human skin cells.
147 citations
,
October 2021 in “Cancer Communications” RC48 shows promise for treating certain advanced cancers, but more research is needed.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Baricitinib is widely used for several conditions, especially COVID-19, but its safety and effectiveness are still being evaluated.
May 2019 in “Journal of clinical oncology” Topical calcitriol was safe and well-tolerated for potential hair loss prevention in chemotherapy patients.
13 citations
,
January 2017 in “Annals of dermatology/Annals of Dermatology” Simvastatin/ezetimibe may help some patients with severe alopecia areata regrow hair.
6 citations
,
November 2023 in “Clinical Pharmacokinetics” Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
6 citations
,
August 2024 in “The Journal of Dermatology” Ozenoxacin reduces sebum production, helping manage acne.
January 2018 in “Springer eBooks” Cancer treatments targeting specific cells often cause skin, hair, and nail problems, affecting patients' lives and requiring careful management.
August 2023 in “Journal of inflammation research” An elderly Chinese man lost all his hair after taking a new heart medication.
3 citations
,
August 2020 in “Cutaneous and Ocular Toxicology” ATP helps prevent skin damage from vandetanib by reducing stress.
January 2002 in “映像情報メディア学会技術報告” Some prostate cancers have gene changes that may affect treatment with certain drugs.
April 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Retinoic acid helps activate hair growth in people with common hair loss by working on a specific cell growth pathway.
Flutamide helps with prostate cancer and some skin conditions but can harm the liver.
January 2026 in “Nature Reviews Urology” 5 citations
,
May 2022 in “Clinical & Experimental Metastasis” Minoxidil and ranolazine together can reduce the spread of certain breast cancer cells.
1 citations
,
December 2011 in “Arzneimittelforschung” CB-03-04 shows promise as a treatment for prostate issues due to its strong anti-androgen effects.
1 citations
,
November 2023 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib helps with early hair regrowth in people with alopecia areata.
January 2025 in “Geneesmiddelenbulletin” Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
March 2022 in “International Journal of Trichology” Erlotinib can cause unusual hair growth, like long eyelashes and facial hair.
February 2006 in “Inpharma Weekly”